Daniel Berlin, MD
Neurology · Ridgewood, NJNPI 1356508741
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $511 of the $579 with a category attached, or 88.2%. 4 manufacturers reported payments, led by AbbVie at 45.4% of the total. Reporting peaked in 2022 at $275 and has fallen 57.0% since, to $118 in 2024. That places this record below the midpoint for neurology clinicians in NJ, where the typical reported total is $1,560.
Across 26 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$263
- Eisai Inc.$118
- Amylyx Pharmaceuticals, Inc.$117
- AstraZeneca$81
What the payments were for
- Food & beverage$51188%
- Education$6812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $263 |
| Eisai Inc. | 1 | $118 |
| Amylyx Pharmaceuticals, Inc. | 1 | $117 |
| AstraZeneca | 3 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$579 in reported general payments places this provider in the 30th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 18 | $14,179 |
| Memantine Hcl | 153 | $7,113 |
| Gabapentin | 158 | $3,467 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 83 | $2,508 |
| Memantine Hcl ErMemantine Hcl | 22 | $2,188 |
| Propranolol Hcl ErPropranolol Hcl | 29 | $2,103 |
| Donepezil Hcl | 145 | $1,995 |
| Carbamazepine ErCarbamazepine | 17 | $1,844 |
| Divalproex Sodium | 24 | $1,797 |
| Levetiracetam | 43 | $1,725 |
| Levetiracetam ErLevetiracetam | 31 | $1,443 |
| Quetiapine Fumarate | 35 | $1,409 |
| Pregabalin | 44 | $1,175 |
| Escitalopram Oxalate | 59 | $823 |
| Atorvastatin Calcium | 30 | $728 |
Paid to pharmacies, not to this prescriber.
Other neurology in Ridgewood
- Kenneth LevinRidgewood$77K
- Dorothea AltschulRidgewood$74K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.